US EditionTeva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook - Teva Pharmaceutical Indus (NYSE:TEVA)
Teva’s innovative brands AUSTEDO, AJOVY, and UZEDY achieved about $1 billion revenue in Q4 2025, driving 4% annual sales growth and supporting fiscal 2026 guidance.
- On Jan. 28, 2026, Teva Pharmaceutical Industries Ltd. reported Q4 2025 revenue of $4.71 billion, beating a $4.37 billion consensus, and said key brands delivered approximately $1 billion in the quarter.
- Driven by development milestone payments and product mix, Teva said Phase 3 starts for duvakitug and higher revenues from AUSTEDO, AJOVY and UZEDY were partially offset by lower proceeds and International Markets revenue after a Japan divestment.
- Key products showed strong gains: AUSTEDO sales rose to $2.26 billion, AJOVY generated $673 million, and UZEDY increased more than 63% to $191 million in 2025 full-year results.
- Teva projected fiscal 2026 revenue of $16.4 billion to $16.8 billion and adjusted EPS of $2.57 to $2.77, while shares fell 0.81% at $31.11, according to Benzinga Pro.
- On the pipeline front, Teva highlights pipeline assets with a potential of over $10 billion, secured up to $500 million in Royalty Pharma funding, submitted an olanzapine LAI NDA in December 2025, and reduced net debt to $13.3 billion.
11 Articles
11 Articles
Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook - Teva Pharmaceutical Indus (NYSE:TEVA)
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported its fourth-quarter 2025 financial results on Wednesday, with total revenue of $4.71 billion, beating analysts' expectations of $4.37 billion, according to Benzinga Pro. Revenues increased 11% year-over-year in U.S. dollars or 9% in local currency. The increase was mainly due to development milestone payments received in connection with the initiation of Phase 3 studies for duvakitug (anti…
Teva shares slide as 2026 forecast disappoints despite strong 2025 earnings
Israel-based pharma giant posts $17.3 billion in 2025 revenue and 19% profit growth, but stock falls on lower-than-expected 2026 outlook, even as CEO touts pipeline potential and billion-dollar quarter from flagship drugs
The pharmaceutical giant reported revenue of $17.3 billion, reflecting annual growth of about 4% • However, its revenue forecast for 2026 is lower than analyst consensus • The stock is down about 3% in early trading on Wall Street
St Catharines Standard
The RecordTeva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues increased 5% YoY in…
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
